A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval-Reference-Cited by-同舟云学术

A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, Three‐Way Crossover Study in Healthy Participants to Investigate the Effect of Savolitinib on the QTc Interval

Published:2021-01-05 Issue:5 Volume:10 Page:521-534
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharmacology in Drug Development

Author:

Sahota Tarjinder¹,Dota Corina D.²,Vik Torbjörn³,Yan Weili⁴,Verheijen Remy B.⁵,Walker Stephen⁶,Li Yan⁷,Goldwater Ronald⁸,Ghiorghiu Dana⁴,Mellemgaard Anders⁴,Ahmed Ghada F.⁹

Affiliation:

1. BioPharmaceuticals R&D, Clinical Pharmacology and Safety Sciences AstraZeneca Cambridge UK

2. Cardiovascular Safety Centre of Excellence, R&D Oncology AstraZeneca Gothenburg Sweden

3. Department of Internal Medicine Hallands Sjukhus Varberg Varberg Sweden

4. Oncology R&D AstraZeneca Cambridge UK

5. Formerly Oncology R&D AstraZeneca Cambridge UK

6. Development Operations, BioPharmaceuticals R&D, Global Medicines Development AstraZeneca Cambridge UK

7. Clinical Pharmacology and Safety Sciences BioPharmaceuticals R&D AstraZeneca Boston Massachusetts USA

8. Parexel International Baltimore Maryland USA

9. Formerly, BioPharmaceuticals R&D Clinical Pharmacology and Safety Sciences AstraZeneca Cambridge UK

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.896

Reference29 articles.

1. Prognostic significance of serum hepatocyte growth factor in clear cell renal cell carcinoma: comparison with serum vascular endothelial growth factor;Tanimoto S;J Med Invest,2008

2. Identification of the Hepatocyte Growth Factor Receptor As the c- met Proto-Oncogene Product

3. MET Exon 14 Mutations in Non–Small-Cell Lung Cancer Are Associated With Advanced Age and Stage-Dependent MET Genomic Amplification and c-Met Overexpression

4. C-Met overexpression in node-positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu

5. Prognostic significance of c-Met expression in glioblastomas

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Savolitinib: A Promising Targeting Agent for Cancer;Cancers;2023-09-25

2. A Phase 1 Study to Evaluate Absolute Bioavailability and Absorption, Distribution, Metabolism, and Excretion of Savolitinib in Healthy Male Volunteers;Clinical Pharmacology in Drug Development;2023-02-19

3. Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib;Therapeutic Advances in Medical Oncology;2023-01

4. The expanding family of c-Met inhibitors in solid tumors: a comparative analysis of their pharmacologic and clinical differences;Critical Reviews in Oncology/Hematology;2022-04

5. Clinical evaluation of the potential drug–drug interactions of savolitinib: Interaction with rifampicin, itraconazole, famotidine or midazolam;British Journal of Clinical Pharmacology;2021-08-21